B. A. C. Cree Et Al. , "Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial," The Lancet Neurology , vol.19, no.12, pp.988-997, 2020
Cree, B. A. C. Et Al. 2020. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology , vol.19, no.12 , 988-997.
Cree, B. A. C., Cutter, G., Wolinsky, J. S., Freedman, M. S., Comi, G., Giovannoni, G., ... Hartung, H.(2020). Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology , vol.19, no.12, 988-997.
Cree, Bruce Et Al. "Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial," The Lancet Neurology , vol.19, no.12, 988-997, 2020
Cree, Bruce A. Et Al. "Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet Neurology , vol.19, no.12, pp.988-997, 2020
Cree, B. A. C. Et Al. (2020) . "Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet Neurology , vol.19, no.12, pp.988-997.
@article{article, author={Bruce A C Cree Et Al. }, title={Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial}, journal={The Lancet Neurology}, year=2020, pages={988-997} }